- Alterity Therapeutics (ATH) has received a US$495,000 (around A$640,428) grant from The Michael J. Fox Foundation for Parkinson’s Research
- The grant allows Alterity to determine the optimal dosing of ATH434 in patients with the disease
- Parkinson’s occurs when the brain cells that make dopamine degenerate and die
- People with Parkinson’s often experience tremors, dementia, dizziness and depression
- The company hopes clinical trials will determine the safety and tolerability of the product
- Alterity is up a healthy 18 per cent on the back of this news with shares trading at 4.6 cents
